Latest news with #Amneal
Yahoo
6 days ago
- Business
- Yahoo
ANI Pharmaceuticals (ANIP) Q2 Earnings: What To Expect
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting earnings this Friday before the bell. Here's what to look for. ANI Pharmaceuticals beat analysts' revenue expectations by 9.8% last quarter, reporting revenues of $197.1 million, up 43.4% year on year. It was a very strong quarter for the company, with a solid beat of analysts' EPS estimates and full-year revenue guidance slightly topping analysts' expectations. Is ANI Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting ANI Pharmaceuticals's revenue to grow 38.7% year on year to $191.5 million, improving from the 18.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.42 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. ANI Pharmaceuticals has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 6.9% on average. Looking at ANI Pharmaceuticals's peers in the pharmaceuticals segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Amneal delivered year-on-year revenue growth of 3.2%, missing analysts' expectations by 2.5%, and Bristol-Myers Squibb reported flat revenue, topping estimates by 7.8%. Amneal's stock price was unchanged after the resultswhile Bristol-Myers Squibb was down 3.9%. Read our full analysis of Amneal's results here and Bristol-Myers Squibb's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the pharmaceuticals stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 5.7% on average over the last month. ANI Pharmaceuticals is up 6.2% during the same time and is heading into earnings with an average analyst price target of $81.38 (compared to the current share price of $69.09). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
7 days ago
- Business
- Yahoo
Amphastar Pharmaceuticals (AMPH) Reports Q2: Everything You Need To Know Ahead Of Earnings
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting results this Thursday after market close. Here's what you need to know. Amphastar Pharmaceuticals missed analysts' revenue expectations by 2% last quarter, reporting revenues of $170.5 million, flat year on year. It was a softer quarter for the company, with a decent beat of analysts' EPS estimates. Is Amphastar Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Amphastar Pharmaceuticals's revenue to decline 3.5% year on year to $176.1 million, a reversal from the 25.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.74 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Amphastar Pharmaceuticals has missed Wall Street's revenue estimates four times over the last two years. Looking at Amphastar Pharmaceuticals's peers in the pharmaceuticals segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Amneal delivered year-on-year revenue growth of 3.2%, missing analysts' expectations by 2.5%, and Supernus Pharmaceuticals reported a revenue decline of 1.7%, topping estimates by 7.4%. Read our full analysis of Amneal's results here and Supernus Pharmaceuticals's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the pharmaceuticals stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Amphastar Pharmaceuticals is down 7.1% during the same time and is heading into earnings with an average analyst price target of $32.20 (compared to the current share price of $21.24). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
7 days ago
- Business
- Yahoo
Viatris (VTRS) Reports Earnings Tomorrow: What To Expect
Medication company Viatris (NASDAQ:VTRS) will be reporting earnings this Thursday before market open. Here's what investors should know. Viatris missed analysts' revenue expectations by 0.7% last quarter, reporting revenues of $3.25 billion, down 11.2% year on year. It was a mixed quarter for the company, with a narrow beat of analysts' full-year EPS guidance estimates but full-year revenue guidance slightly missing analysts' expectations. Is Viatris a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Viatris's revenue to decline 9.5% year on year to $3.44 billion, a further deceleration from the 3.1% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.56 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Viatris has missed Wall Street's revenue estimates six times over the last two years. Looking at Viatris's peers in the pharmaceuticals segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Amneal delivered year-on-year revenue growth of 3.2%, missing analysts' expectations by 2.5%, and Supernus Pharmaceuticals reported a revenue decline of 1.7%, topping estimates by 7.4%. Read our full analysis of Amneal's results here and Supernus Pharmaceuticals's results here. The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the pharmaceuticals stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Viatris is down 2.3% during the same time and is heading into earnings with an average analyst price target of $11.14 (compared to the current share price of $8.99). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Yahoo
7 days ago
- Business
- Yahoo
Viatris (VTRS) Reports Earnings Tomorrow: What To Expect
Medication company Viatris (NASDAQ:VTRS) will be reporting earnings this Thursday before market open. Here's what investors should know. Viatris missed analysts' revenue expectations by 0.7% last quarter, reporting revenues of $3.25 billion, down 11.2% year on year. It was a mixed quarter for the company, with a narrow beat of analysts' full-year EPS guidance estimates but full-year revenue guidance slightly missing analysts' expectations. Is Viatris a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Viatris's revenue to decline 9.5% year on year to $3.44 billion, a further deceleration from the 3.1% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.56 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Viatris has missed Wall Street's revenue estimates six times over the last two years. Looking at Viatris's peers in the pharmaceuticals segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Amneal delivered year-on-year revenue growth of 3.2%, missing analysts' expectations by 2.5%, and Supernus Pharmaceuticals reported a revenue decline of 1.7%, topping estimates by 7.4%. Read our full analysis of Amneal's results here and Supernus Pharmaceuticals's results here. The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the pharmaceuticals stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Viatris is down 2.3% during the same time and is heading into earnings with an average analyst price target of $11.14 (compared to the current share price of $8.99). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
San Francisco Chronicle
05-08-2025
- Business
- San Francisco Chronicle
Amneal: Q2 Earnings Snapshot
BRIDGEWATER, N.J. (AP) — BRIDGEWATER, N.J. (AP) — Amneal Pharmaceuticals, Inc. (AMRX) on Tuesday reported second-quarter net income of $22.4 million. On a per-share basis, the Bridgewater, New Jersey-based company said it had net income of 7 cents. Earnings, adjusted for amortization costs and non-recurring costs, were 25 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 18 cents per share. Amneal expects full-year revenue in the range of $70 million to $75 million. Amneal shares have risen 0.5% since the beginning of the year. The stock has risen 14% in the last 12 months. _____
